Clinical Trial Update: A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin's Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial evaluating the safety and efficacy of nivolumab plus bendamustine in relapsed/refractory Hodgkin's lymphoma has completed phases 1 and 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• nivolumab (nivolumab)

Snippet

Sponsor: St. Petersburg State Pavlov Medical University | Conditions: Hodgkin's Lymphoma | Phase 1, Phase 2 | Status: COMPLETED